Nucleos(t)ide analogue therapy for HBV-related HCC after hepatic resection: clinical benefits and unanswered questions.
about
Impact of oral anti-hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization.Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection.Feasibility of combining adjuvant transarterial chemoembolization with nucleos(t)ide analog therapy for patients with HBV-associated hepatocellular carcinoma after hepatectomy.Adefovir dipivoxil is less expensive than lamivudine and associated with similar prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after radical resection.Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinomaChanges of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment.Perioperative entecavir for patients with HBV-related hepatocellular carcinoma and low levels of viral DNA: analysis using propensity score matching.Comment on "Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis".Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after surgery: A comment for moving forward.Efficacy of combined adjuvant transarterial chemoembolization and antiviral therapy in patients with HBV-related hepatocellular carcinoma after surgery.Letter: which patients with hepatitis B virus-related hepatocellular carcinoma should receive nucleos(t)ide analogue therapy?Letter: should anti-viral therapy be recommended for individuals chronically infected with hepatitis B virus and at low risk of hepatocellular carcinoma?The STORM trial and beyond: narrowing the horizon of adjuvant sorafenib for postoperative hepatocellular carcinoma.
P2860
Q36121202-32CBBEE5-D31B-4913-973B-C1DDF2C63E5CQ36705411-1265314E-D22F-4D6C-BCC5-FC93280C667AQ37001714-AB30B397-E47A-40C7-9ECE-6047B618FC22Q37413142-985AC61D-1500-43CE-9006-AFE18E40754BQ37716493-A5AC4B69-DB95-401C-853C-4250FCDCD389Q38815080-807AD93A-9EAF-4171-9E2D-43AF6FF297C7Q40053236-16206BD3-C2FB-4AF5-9DEC-E31786B7A17EQ40631428-BD2D1347-CA42-4DBB-B1F6-8853BAC1A105Q40759290-BC37B069-C37A-4B30-803C-437D8DA4E39BQ41404394-F5D44EC0-18D3-414D-BF7C-744F4DCD3BAFQ45028850-4D286690-9C9C-4849-8503-67ED8181C380Q45331750-A73AB359-5B88-491F-9BEC-F2FDECEEED57Q53300584-713A33B0-50EB-480A-9ED5-F52D814F63EF
P2860
Nucleos(t)ide analogue therapy for HBV-related HCC after hepatic resection: clinical benefits and unanswered questions.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Nucleos(t)ide analogue therapy ...... fits and unanswered questions.
@en
type
label
Nucleos(t)ide analogue therapy ...... fits and unanswered questions.
@en
prefLabel
Nucleos(t)ide analogue therapy ...... fits and unanswered questions.
@en
P2860
P1433
P1476
Nucleos(t)ide analogue therapy ...... efits and unanswered questions
@en
P2093
Jian-Hong Zhong
P2860
P2888
P304
12779-12784
P356
10.1007/S13277-014-2881-1
P577
2014-11-28T00:00:00Z